Skylark Therapeutics establishes operations at Stevenage Bioscience Catalyst
- Published on 4th February 2022 by Laverock Therapeutics
SkylarkTx has established lab and office facilities at the Stevenage Bioscience Catalyst, the UK’s leading cell and gene therapy hub.
David Venables, SkylarkTx CEO, commented ‘SBC provides an ideal home for Skylark to initiate operations, establish lab facilities and to build its Team. The world class environment allows us to work alongside leading companies in the CGTC space and will help foster a dynamic and collaborative working environment.’
Other news
-
GenScript Named a BioSpace 2024 Best Place to WorkPublished on 1 Dec 2023 -
New UK-India research project trialling easy-to-use test to help fight against global threat of antimicrobial resistancePublished on 30 Nov 2023 -
Advanced Therapies Integrates comes to Stevenage – the home of cell and gene therapiesPublished on 30 Nov 2023 -
Leading industry surveys demonstrate continued growth in the UK’s cell and gene therapy sectorPublished on 24 Nov 2023
Copyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.